AUTL

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.20
Percentage change -7.43	%

Peers: BLUE CRSP EDIT IOVA NTLA SRPT PSTX TCRT ADPT BOLT

| Held by: IBB KOMP MOON GWX CNCR BBC FFSM BIB QQQS IBBQ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.21	Insider Own	11.06%	Shs Outstand	266.12M	Perf Week	-15.31%
Market Cap	662.64M	Forward P/E	-	EPS next Y	-0.78	Insider Trans	0.00%	Shs Float	236.67M	Perf Month	-24.32%
Income	-270.23M	PEG	-	EPS next Q	-0.21	Inst Own	56.29%	Short Float	2.66%	Perf Quarter	-37.75%
Sales	10.09M	P/S	65.67	EPS this Y	24.87%	Inst Trans	-4.32%	Short Ratio	3.96	Perf Half Y	-44.67%
Book/sh	1.79	P/B	1.39	EPS next Y	13.03%	ROA	-43.81%	Short Interest	6.29M	Perf Year	-48.66%
Cash/sh	2.47	P/C	1.01	EPS next 5Y	-	ROE	-82.20%	52W Range	2.69 - 7.45	Perf YTD	-61.34%
Dividend Est.	-	P/FCF	-	EPS past 5Y	3.32%	ROI	-34.89%	52W High	-66.58%	Beta	2.01
Dividend TTM	-	Quick Ratio	13.64	Sales past 5Y	190.29%	Gross Margin	26.53%	52W Low	-7.43%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	13.64	EPS Y/Y TTM	-22.72%	Oper. Margin	-2039.55%	RSI (14)	28.98	Volatility	6.81% 7.54%
Employees	463	Debt/Eq	0.63	Sales Y/Y TTM	82.71%	Profit Margin	-2677.90%	Recom	1.00	Target Price	10.76
Option/Short	Yes / Yes	LT Debt/Eq	0.62	EPS Q/Q	-17.08%	Payout	-	Rel Volume	2.61	Prev Close	2.69
Sales Surprise	-100.00%	EPS Surprise	-44.66%	Sales Q/Q	-100.00%	Earnings	Nov 12 BMO	Avg Volume	1.59M	Price	2.49
SMA20	-16.35%	SMA50	-30.62%	SMA200	-40.50%	Trades		Volume	4,141,649	Change	-7.43%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-24	Upgrade	Goldman	Neutral → Buy	$7 → $7.60
Nov-15-24	Upgrade	Redburn Atlantic	Neutral → Buy	$13
Nov-09-23	Initiated	Deutsche Bank	Buy	$10
Mar-27-23	Resumed	Wells Fargo	Overweight	$8
Mar-17-23	Initiated	Bryan Garnier	Buy	$5
Jun-14-21	Upgrade	Jefferies	Hold → Buy	$6 → $12
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral	$9
Dec-28-20	Resumed	H.C. Wainwright	Buy	$19
Jul-31-20	Initiated	JP Morgan	Overweight
Jul-22-20	Initiated	SunTrust	Buy	$38
Apr-22-20	Initiated	Mizuho	Buy	$18
Sep-23-19	Initiated	Needham	Buy	$26
May-17-19	Reiterated	H.C. Wainwright	Buy	$45 → $41
Oct-24-18	Initiated	H.C. Wainwright	Buy	$45

Show Previous Ratings

Dec-09-24 07:30PM	Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 (GlobeNewswire)
Dec-05-24 07:12PM	Autolus Therapeutics plc (AUTL): A Bull Case Theory (Insider Monkey)
Dec-02-24 07:00AM	Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine (GlobeNewswire)
Nov-19-24 06:11AM	Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs (TipRanks)
Nov-15-24 02:03AM	Syncona Ltd (LSE:SYNC) Half Year 2025 Earnings Call Highlights: Navigating Market Challenges ... (GuruFocus.com)
02:09AM	Loading…
Nov-13-24 02:09AM	Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
02:03AM	Q3 2024 Autolus Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
Nov-12-24 07:00AM	Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates (GlobeNewswire) -5.13%
Nov-11-24 04:19PM	These Stocks Moved the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More (Barrons.com) -5.90%
02:23PM	These Stocks Are Moving the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More (Barrons.com)
12:53PM	Autolus secures FDA approval for CAR-T cell therapy use in ALL (Pharmaceutical Technology)
07:12AM	What To Expect From Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings (GuruFocus.com)
07:04AM	FDA approves new CAR-T competitor to Gileads Tecartus (BioPharma Dive)
Nov-08-24 04:23PM	Autolus Therapeutics Announces FDA Approval of AUCATZYL (obecabtagene autoleucel obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) (GlobeNewswire) -7.67%
Nov-05-24 09:00AM	Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations (GlobeNewswire)
05:00PM	Loading…
Oct-28-24 05:00PM	Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 (GlobeNewswire)
Oct-17-24 02:29PM	Autolus Therapeutics (AUTL): High-Growth UK Stock in Cancer Therapy (Insider Monkey)
Oct-16-24 09:00AM	Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress (GlobeNewswire) +5.87%
08:58AM	Why Autolus Therapeutics plc (AUTL) is the Penny Stock with the Biggest Upside Potential According to Analysts (Insider Monkey)
Oct-09-24 05:37PM	Autolus Therapeutics PLC (AUTL) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Sep-19-24 07:00AM	Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer (GlobeNewswire)
Sep-12-24 04:18PM	Autolus Therapeutics PLC (AUTL): Fast-Growing Penny Stock To Consider (Insider Monkey)
Sep-01-24 10:26PM	Autolus Therapeutics plc (AUTL): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
Aug-27-24 07:00AM	Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024 (GlobeNewswire)
Aug-08-24 07:00AM	Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates (GlobeNewswire) -9.45%
Jul-26-24 07:00AM	Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 (GlobeNewswire)
Jun-14-24 07:00AM	Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress (GlobeNewswire)
Jun-13-24 02:31PM	Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget (InvestorPlace)
May-31-24 08:00AM	Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO (GlobeNewswire) +5.01%
08:09AM	Loading…
May-19-24 08:09AM	Autolus Therapeutics plc (NASDAQ:AUTL) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-18-24 02:42AM	Q1 2024 Autolus Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
May-17-24 01:52PM	AUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +7.86%
07:42AM	Autolus Therapeutics' Q1 Loss Widens, Licensing Revenue Rises (MT Newswires)
07:00AM	Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
May-14-24 10:00AM	Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress (GlobeNewswire)
May-13-24 11:15AM	Autolus Therapeutics Announces Delay of Q1 Earnings Release (MT Newswires)
07:00AM	Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call (GlobeNewswire)
Apr-24-24 10:00AM	Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO (GlobeNewswire) -6.03%
Apr-23-24 07:00AM	Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 (GlobeNewswire)
Apr-02-24 07:00AM	Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) (GlobeNewswire)
Apr-01-24 07:00AM	Autolus Therapeutics Announces Changes to its Board of Directors (GlobeNewswire) -10.97%
Mar-21-24 01:43AM	Q4 2023 BioNTech SE Earnings Call (Thomson Reuters StreetEvents)
Mar-17-24 09:19AM	Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-15-24 05:53AM	Q4 2023 Autolus Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
Mar-14-24 01:51PM	Autolus Therapeutics PLC Reports Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates (GlobeNewswire)
Mar-12-24 07:00AM	Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site (GlobeNewswire)
Mar-11-24 07:00AM	Autolus Therapeutics announces publication in Blood Cancer Journal (GlobeNewswire) -5.25%
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-29-24 07:00AM	Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024 (GlobeNewswire)
Feb-22-24 07:00AM	Autolus Therapeutics announces publication in Nature Communications (GlobeNewswire)
Feb-12-24 02:29AM	Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength? (Zacks) +9.56%
Feb-08-24 07:00AM	Autolus Announces Pricing of Underwritten Offering (GlobeNewswire) -5.06%
06:07AM	BioNTech partners with Autolus to boost cell therapy manufacturing (BioPharma Dive)
05:45AM	BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs (GlobeNewswire)
Jan-23-24 07:00AM	Autolus Therapeutics announces publication in ACS Chemical Biology (GlobeNewswire)
Jan-22-24 07:00AM	Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL) (GlobeNewswire) -5.89%
Jan-10-24 07:00AM	Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors (GlobeNewswire)
Dec-22-23 07:00AM	Autolus Therapeutics Announces Changes to its Board of Directors (GlobeNewswire)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-09-23 08:30PM	Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 (GlobeNewswire)
Nov-27-23 07:00AM	Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL) (GlobeNewswire)
Nov-15-23 07:00AM	Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023 (GlobeNewswire) +7.34%
Nov-06-23 07:00AM	Autolus Therapeutics announces participation in upcoming conferences (GlobeNewswire) -9.54%
Nov-05-23 05:34PM	Autolus Therapeutics plc (NASDAQ:AUTL) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 09:00AM	Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations (GlobeNewswire) +14.92%
07:11AM	Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Oct-17-23 07:00AM	Autolus Therapeutics to host virtual event to discuss the company's obe-cel program in systemic lupus erythematosus (GlobeNewswire) +7.26%
Oct-11-23 08:07AM	Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023 (GlobeNewswire)
07:00AM	Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023 (GlobeNewswire)
Sep-05-23 07:00AM	Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood (GlobeNewswire) -5.99%
Aug-07-23 04:32PM	Autolus Therapeutics plc (NASDAQ:AUTL) Q2 2023 Earnings Call Transcript (Insider Monkey) -5.30%
Aug-04-23 06:29AM	Autolus Therapeutics (NASDAQ:AUTL) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-03-23 07:00AM	Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress (GlobeNewswire)
Jul-19-23 07:00AM	Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer (GlobeNewswire) +5.06%
Jul-18-23 07:00AM	Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023 (GlobeNewswire)
Jul-06-23 07:00AM	Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia (GlobeNewswire)
Jun-27-23 07:00AM	Autolus Therapeutics announces publication in Cancer Immunology Research (GlobeNewswire)
Jun-20-23 07:00AM	Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director (GlobeNewswire)
Jun-16-23 07:00AM	Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma (GlobeNewswire)
Jun-14-23 09:39AM	3 Top Penny Stock Picks You Havent Heard Of (InvestorPlace)
Jun-06-23 07:00AM	Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023 (GlobeNewswire)
Jun-04-23 07:11AM	10 Hot Penny Stocks To Buy (Insider Monkey)
Jun-02-23 07:00AM	Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO (GlobeNewswire) -7.35%
May-22-23 07:00AM	Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL (GlobeNewswire) +8.84%
May-12-23 07:00AM	Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA (GlobeNewswire) +10.81%
May-04-23 07:00AM	Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress (GlobeNewswire)
May-01-23 10:15AM	Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply (Zacks)
Apr-27-23 07:01AM	Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO (GlobeNewswire) +5.49%
07:00AM	Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner (GlobeNewswire)
Apr-26-23 04:01PM	Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids (GlobeNewswire) -5.20%
07:06AM	Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting (GlobeNewswire)
Apr-25-23 07:00AM	Autolus Therapeutics to Host Virtual Capital Markets Day (GlobeNewswire)
Apr-20-23 07:00AM	Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023 (GlobeNewswire)
Apr-16-23 09:30AM	12 Best Low-Priced Growth Stocks To Buy (Insider Monkey)
Apr-14-23 11:08AM	Autolus Therapeutics (NASDAQ:AUTL) shareholders have endured a 79% loss from investing in the stock three years ago (Simply Wall St.)
Apr-04-23 07:00AM	Autolus Therapeutics Announces Publication in Molecular Therapy (GlobeNewswire) -6.19%
Mar-14-23 07:00AM	Autolus Therapeutics announces resignation of Chief Financial Officer (GlobeNewswire)
Mar-13-23 07:00AM	Autolus Therapeutics Has No Business Relationship with Silicon Valley Bank (GlobeNewswire) +6.32%

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Martin Pule	Officer	Sep 16 '24	Proposed Sale	4.23	698,741	2,955,674		Sep 16 05:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Autolus Therapeutics plc ADR

Upgrade your FINVIZ experience